

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-7. (Canceled)

8. (Previously Presented) A method comprising  
performing density gradient centrifugation on bone marrow; and  
isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml.

9. (Previously Presented) The method according to claim 1, wherein said performing uses  
an isotonic solution of Ficoll® or Percoll®.

10. (Previously Presented) The method according to claim 2, wherein said isotonic solution  
is Percoll® and said density is 1.068 g/ml.

11. (Currently Amended) A mesenchymal stem cell obtained according to a method ~~of claim~~  
~~8 comprising~~  
performing density gradient centrifugation on bone marrow; and  
isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml.

12. (Currently Amended) [[A]] The mesenchymal stem cell obtained according to a method  
of claim [[9]]11 wherein said performing uses an isotonic solution of Ficoll® or Percoll®.

13. (Currently Amended) [[A]] The mesenchymal stem cell obtained according to a method  
of claim [[10]]12 wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.

14. (Currently Amended) A pharmaceutical preparation comprising a mesenchymal stem cell  
obtained according to a method comprising  
performing density gradient centrifugation on bone marrow; and

isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml according to claim 11.

15. (Currently Amended) [[A]] The pharmaceutical preparation comprising a mesenchymal stem cell according to of claim [[12]]14 wherein said performing uses an isotonic solution of Ficoll® or Percoll®.

16. (Currently Amended) [[A]] The pharmaceutical preparation comprising a mesenchymal stem cell according to of claim [[13]]15 wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.

17. (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 14 further comprising formulating isolated mesenchymal stem cells according to claim 1 and a pharmaceutically acceptable excipient and/or carrier.

18. (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 15 further comprising formulating isolated mesenchymal stem cells according to claim 2 and a pharmaceutically acceptable excipient and/or carrier.

20. (Currently Amended) A method of manufacturing a The pharmaceutical preparation of claim 16 further comprising formulating isolated mesenchymal stem cells according to claim 3 and a pharmaceutically acceptable excipient and/or carrier.